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Abstract
KRAS mutations are the most common mutations in non-small cell lung cancer (NSCLC) with 
adenocarcinoma histology. KRAS mutations result in the activation of the RAF-MEK-ERK 
pathway, and agents that target RAF-MEK-ERK pathways have been investigated in KRAS 
mutant NSCLC. The two agents furthest in development are selumetinib and trametinib. 
Trametinib has greater binding for the MEK1/2 allosteric site, and generally has superior 
pharmacokinetics. A randomized phase II trial of docetaxel with and without selumetinib revealed 
that the combination resulted numerically superior overall survival, and a statistically significant 
improvement in progression-free survival and objective response rate. However, a concerning rate 
of hospital admission, grade 3 or 4 neutropenia, and febrile neutropenia was observed with the 
combination. Trials have investigated MEK inhibitors as single agents, and in combination with 
erlotinib or chemotherapy. The data do not support the further development of single agent MEK 
inhibitors or in combination with erlotinib. The activity of MEK inhibitors appears to be similar in 
patients with KRAS mutant and wild-type NSCLC suggesting KRAS mutation status is not a 
reliable biomarker for efficacy. It is possible that mutations of genes in addition to KRAS 
mutations impact the activity of MEK inhibitors, or specific subsets of KRAS mutations may be 
resistant or susceptible to MEK inhibition. Other potential explanations are gene amplifications, 
alternative RNA splicing of genes resulting in activation of their protein products, and 
deregulation of noncoding RNAs and consequent altered protein expression.
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Historically non-small cell lung cancer (NSCLC) was considered a single monolithic 
disease, and all patients with stage IIIB or IV disease who were eligible for chemotherapy 
received a platinum doublet regardless of histology or tumor biology. Unfortunately this 
approach resulted in limited progress, and the vast majority of trials of different platinum-
based combinations did not result in an improvement in overall survival (OS).1,2 The 
identification of the epidermal growth factor receptor (EGFR) mutations and anaplastic 
lymphoma kinase (ALK) rearrangements, and the development of EGFR tyrosine kinase 
inhibitors (TKI) and ALK inhibitors changed the diagnostic and therapeutic approach to the 
treatment of NSCLC.3–5 These agents resulted in substantial improvement in the treatment 
of patients with NSCLC with these specific molecular alterations. As tumor gene sequencing 
became more rapid and affordable, the focus of NSCLC research changed to the 
identification and development of therapies for NSCLC with specific molecular 
abnormalities.6 While the majority of the research focus in NSCLC has been on the role of 
mutation or rearrangements, it is important to note other molecular events such as 
amplification or overexpression may also be oncogenic drivers.
KRAS mutations are the most common mutations in NSCLC, and unfortunately a targeted 
therapy currently is currently not available for this patient population. KRAS mutations are 
associated with adenocarcinoma histology and a history of tobacco use. A recent analysis of 
resected NSCLC showed the rate of KRAS mutations in adenocarcinoma and squamous 
NSCLC was 34% and 6%, respectively.7 The rate of KRAS mutations among former or 
current smokers compared to never smokers in a recent meta-analysis was significantly 
higher (25% vs. 6%, p<0.01).8 Previous clinical trials investigated agents that target the 
KRAS pathway by either by directly targeting the RAS protein or by inhibiting downstream 
proteins in the MEK-ERK or the PI3K-AKT-mTOR pathways.9,10 MEK inhibitors are the 
most promising targeted therapy for patients with advanced KRAS mutant NSCLC to date. 
However, the activity of MEK inhibitors may not be limited to KRAS mutant NSCLC and 
may be synergistic with chemotherapy. To date MEK inhibitors have been investigated as 
single agents, in combinations with chemotherapy and EGFR TKI therapy, and in KRAS 
mutant and wild-type NSCLC.
Currently all KRAS mutations are considered to be the same biologically and clinically, but 
the situation may be more complex. Retrospective studies suggest that patients with a KRAS 
mutation and history of never smoking are more likely to have transition mutations rather 
than transversion mutation, but the clinical significance of this is unclear.11 Preclinical 
evidence suggests that the different KRAS mutations may differentially impact downstream 
signaling pathways of MEK-ERK or PI3k-AKT-mTOR. Mutant KRAS (G12C) 
preferentially binds the Ral guanine nucleotide dissociation stimulator whereas KRAS 
(G12D) has a higher affinity for the PI3K pathway.12 Retrospective data from a four-arm 
trial of targeted therapies (erlotinib, vandetanib, bexarotene and erlotinib, and sorafenib) 
revealed that patients with KRAS G12C and G12V mutations (n=24) compared to patients 
with other KRAS mutations (n=19) or KRAS wild-type tumors (n=172) experience a 
statistically significant shorter progression-free survival (p=0.046).12 Given the multiple 
therapies investigated and the small number of patients in each cohort these data are 
hypothesis generating. However, it raises the possibility that the biology of KRAS mutations 
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may differ, and the efficacy of targeted therapies may be related to the specific KRAS 
mutation.
Many times NSCLC is perceived as having a single oncogenic driver mutation, but 
concurrent mutations may exist and this may impact the efficacy of targeted therapy.13 
Using genetically engineered mouse models to assess the efficacy of selumetinib studies 
demonstrated the concomitant loss of tumor suppressor genes p53 or Lkb1 reduced the 
response of KRAS mutant lung cancers to single agent docetaxel.14 Mouse models with 
KRAS alone and KRAS and p53 mutations revealed significant benefit with the addition 
selumetinib with docetaxel compared to docetaxel alone; mice with KRAS and 
Lkb1mutations were resistant to the combination of docetaxel and selumetinib. Thus, the 
presence of a second mutation may influence the activity of MEK inhibitors.
MAPK kinase pathway
Figure 1 shows the three-tiered MAPK pathway that is regulated by RAS (KRAS, HRAS, 
NRAS) binding to BRAF or RAF1, which are mitogen-activated protein kinases (MAP3Ks). 
MAP3Ks phosphorylate and activate MAP-ERK kinases 1 and 2 (MEK1/2), both of which 
phosphorylate and activate extracellular signal-regulated kinases (ERK1 and 2). The 
importance of the RAF-MEK-ERK pathway is demonstrated by the important functions that 
ERK1/2 substrates regulate including proliferation, survival, translation, lipid metabolism, 
transcription and protein acetylation. In addition to RAF proteins there are additional 
MAP3Ks including MAP3K8 (TPL2/COT) and MAP3K1 (MEKK1) that are able to 
phosphorylate and activate MEK1/2. MAP3K1 and MAP3K8 are not directly regulated by 
RAS but are mutated or amplified in different cancers.15 There are two approved RAF 
inhibitors, vemurafenib and dabrafenib, that are used clinically in cancers with activating 
BRAF mutations such as malignant melanoma.16,17 BRAF inhibitors are not used to treat 
tumors with wild-type BRAF because of a paradoxical RAF activation seen with wild-type 
but not mutant BRAF leading to strong ERK1/2 activation resulting in tumor cell 
proliferation.18
There are currently two MEK1/2 inhibitors, selumetinib and trametinib, that have been 
tested in many different cancer types including NSCLC with several more MEK inhibitors at 
different stages of clinical testing. Trametinib has been approved in combination with 
dabrafenib for melanoma. ERK1/2 inhibitors such as SCH772984 are also in development 
and have shown efficacy for BRAF inhibitor resistant melanoma.19 Whereas the BRAF and 
ERK1/2 inhibitors compete with ATP at the active site of the kinase, MEK1/2 inhibitors 
such as selumetinib and trametinib bind to an allosteric regulatory site independent of the 
ATP binding site. Trametinib has a greater affinity than selumetinib for the MEK1/2 
allosteric regulatory site and generally has superior pharmacokinetics. A single oral dose of 
trametinib has a long serum half-life and is able to inhibit ERK1/2 activity in tumors for 
more than 24 hours.20
MEK1/2 inhibitors have their greatest antitumor effects with tumors harboring RAS or BRAF 
activating mutations because the RAF-MEK-ERK pathway is generally activated and 
contributes significantly to tumor cell proliferation and survival. However, there are 
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examples where MEK inhibitors have significant efficacy with tumors that do not have 
activating RAS or BRAF mutations. For example, in basal-like triple negative breast cancer 
where activating RAS or BRAF mutations are rare; however, the RAF-MEK-ERK pathway is 
often activated due to genomic amplification of EGFR, KRAS or BRAF.21 In fact, EGFR, 
KRAS and BRAF were amplified 22%, 32% and 31%, respectively, in basal-like triple 
negative breast cancers. This is an excellent example of the importance of understanding the 
genomic landscape of an individual’s tumor where amplification and not activating 
mutations are driving a critical signaling pathway in tumor cells. In addition to gene 
amplification alternative RNA splicing has been shown to result in BRAF activation.22 
Deregulation of noncoding RNAs may also alter expression of proteins that could result in 
the activation of the MAPK kinase pathway resulting in the tumor being vulnerable to MEK 
inhibition.
MEK inhibitors in combination with chemotherapy
Selumetinib is an oral, selective inhibitor of the MEK1/MEK2 kinases, and preclinical data 
using KRAS mutant NSCLC xenograft models indicated that selumetinib significantly 
inhibited tumor growth.23 The most common toxicities observed in the phase I and phase II 
trials of single agent selumetinib were rash, mild to moderate diarrhea, fatigue and 
edema.24,25 In the phase I and II single agent trials no episodes of grade 3 or 4 neutropenia 
were observed. A prospective phase II trial of docetaxel (75 mg/m2 every 3 weeks) with and 
without selumetinib in patients with KRAS mutant NSCLC who had progressed after first-
line chemotherapy was performed.26 The primary end-point was OS, and secondary end-
points were PFS and objective response rate (ORR). Patients assigned to the selumetinib and 
docetaxel (n=44) compared to the docetaxel alone arm (n=43) experienced a statistically 
non-significant improvement in OS (hazard ratio (HR) of 0.80, 80% confidence interval (CI) 
0.56 to 1.14; p=0.21; median 9.4 and 5.2 months, respectively), but a statistically significant 
improvement in PFS (HR of 0.58, 80% CI, 0.42 to 0.79; p =0.014, median 5.3 and 2.1 
months, respectively) and ORR (37% vs. 0%, p<0.0001). The rates of adverse events 
leading to hospital admission in the selumetinib and docetaxel and the docetaxel alone arms 
were 48% and 19%, respectively. The rates of febrile neutropenia in the selumetinib and 
docetaxel and docetaxel alone arms were 18% and 0%, respectively.
A phase III trial of docetaxel (75 mg/m2 every 3 weeks) with selumetinib or placebo in 
patients with KRAS mutant NSCLC is ongoing (NCT01933932).27 The primary end-point is 
PFS, and secondary endpoints are OS, ORR and symptom improvement rate and time to 
symptom progression. Patients in both arms receive prophylactic pegylated granulocyte 
colony stimulating factor (GCSF). A phase II three arm trial is investigating selumetinib 
with docetaxel 75 mg/m2 or 60 mg/m2 every 3 weeks and docetaxel alone at 75 mg/m2 
every 3 weeks in patients with KRAS wild-type NSCLC; the primary end-point is PFS 
(NCT01750281).27
Trametinib is an oral, selective inhibitor of MEK1/MEK2 kinases, and in cell line and 
xenograft models it demonstrated activity in RAS mutant models.28 A phase I trial revealed 
acceptable toxicity, and the doselimiting toxicities were rash, diarrhea, and central serous 
retinopathy.29 RAS mutant cell line data suggested synergism between trametinib and 
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docetaxel.30 A phase I/Ib trial investigated the combination of trametinib with docetaxel, 
and patients with KRAS mutant (Table 1) and KRAS wild-type NSCLC (Table 2) were 
enrolled.31 The phase I trial design was dose escalation of trametinib and docetaxel, and the 
second part of the trial was an expansion cohort with the recommended dose for phase II 
trials in the KRAS mutant and wild-type cohorts. GCSF support was mandatory. The most 
common non-hematological grade 3 or 4 adverse events observed were diarrhea (11%), 
fatigue (4%), asthenia (4%), dyspnea (4%), mucosal inflammation (4%), and increased liver 
tests (4%). The hematologic grade 3 or 4 toxicities observed were anemia (15%), 
neutropenia (19%), and febrile neutropenia (4%). The ORR (as assessed by the investigator) 
observed in evaluable patients with KRAS mutant (n=21) and KRAS wild-type (n=19) was 
28%, and 32%, respectively. A subset analysis of the patients with KRAS G12C mutation 
(n=8) revealed a response rate of 40% and a disease control rate of 80%. A similar phase 
I/Ib trial investigated trametinib in combination with pemetrexed in KRAS mutant and wild-
type NSCLC.32 The trial design was similar, but GCSF were not required. The most 
common grade 3 or 4 non-hematological adverse events observed were asthenia (10%), 
nausea (7%), dyspnea (7%), diarrhea (5%), and decreased appetite (5%). The grade 3 or 4 
hematological events were anemia (14%) and neutropenia (21%). The ORR (as assessed by 
the investigator) in evaluable patients with KRAS mutant (n=22) and wild-type (n=15) 
NSCLC was 17% and 15%, respectively. The median PFS in the KRAS mutant and wild-
type patients were similar (Tables 1 and 2).
MEK inhibitors in combination with erlotinib
The combination of selumetinib and erlotinib was investigated in two parallel randomized 
phase II trials.33 Patients with KRAS mutant NSCLC were randomized to selumetinib alone 
or erlotinib and selumetinib and the primary end-point was ORR; patients with KRAS wild-
type NSCLC were randomized to erlotinib alone or erlotinib and selumetinib and the 
primary end-point was PFS. Among patients with the KRAS mutant the ORR was higher in 
the combination arm than in the single arm, but the median progression free survival was 
similar in the two arms. In the KRAS wild-type NSCLC the ORR and the median PFS were 
similar on the two treatment arms (Table 2). The limited activity of single agent erlotinib in 
patients with KRAS mutant NSCLC raises concerns about the pairing of MEK inhibitors 
with EGFR TKI’s.34 At this time the data do not support further investigation of the 
combination of MEK inhibitors and EGFR TKI therapy.
Single agent MEK inhibitors
Several trials have investigated single agent MEK inhibitors. A randomized phase II trial of 
single agent selumetinib compared to pemetrexed in patients with advanced NSCLC who 
had progressed after one or two lines of therapy revealed limited single agent activity of 
selumetinib (n=84). Patients were not selected based on KRAS status or for non-squamous 
histology.25 The PFS observed in the selumetinib and pemetrexed arms was similar (HR of 
1.08, 80% CI, 0.75 to 1.54; p=0.79), and two patients in each arm experienced a response. 
More recently single agent trametinib was compared to docetaxel in randomized phase II 
trial in patients with KRAS mutant NSCLC (n=129). Patients assigned to trametinib 
compared to docetaxel experienced a similar PFS (HR of 1.14, 95% CI, 0.75–1.75; 
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p=0.5197), and the ORR was the same in both arms (12%).35 The data do not suggest a role 
for single agent MEK inhibitors in KRAS mutant or unselected patients with advanced 
NSCLC.
A phase I trial with an expansion cohort investigated the MEK inhibitor RO2987655 
(CH4987655) in patients with advanced cancer and RAS-RAF mutations.36,37 The 
treatment-related adverse events observed were asymptomatic increase in creatinine 
phosphokinase (17%), rash (16%), diarrhea (8%), folliculitis (7%), and serous retinal 
detachment (6%). Of the 95 patients enrolled 24 patients had KRAS mutant NSCLC, and 18 
patients were evaluable for response. The ORR observed among patients with KRAS mutant 
NSCLC was 11% (2 of 18 patients) and 44% of patients had stable disease for ≥ 8 weeks (8 
patients). Post-treatment biopsies on cycle 1 day 15 of NSCLC tumors revealed a significant 
down-regulation of phosphorylated ERK expression was observed (p<0.009); however, a 
significant reduction of Ki-67 expression was not observed.
Conclusions
While the preliminary clinical trials of MEK inhibitors in NSCLC have been focused on 
patients with KRAS mutant NSCLC the preclinical data and clinical data suggests that the 
activity of MEK inhibitors is not limited to the KRAS mutant subtype of NSCLC. The data 
suggest further development of MEK inhibitors should be in combination with 
chemotherapy rather than in combination with erlotinib or as single agents. Selumetinib is 
the agent furthest in development, and a randomized phase II trial revealed promising 
activity but a concerning rate of hospitalization, grade 3 or 4 neutropenia, and febrile 
neutropenia. The ongoing trials investigating selumetinib and docetaxel include prophylactic 
GCSF or investigate a reduced dose of docetaxel to reduce the rate of grade 3 or 4 
neutropenia and febrile neutropenia. These trials should define the role of selumetinib in the 
KRAS mutant and wild-type patient populations. Selumetinib is further in development, but 
trametinib has greater affinity for MEK1/2 allosteric regulatory site, and warrants further 
investigation. Several other MEK inhibitors are in development and will be investigated in 
clinical trials as well. While the primary focus of developing MEK inhibitors in NSCLC has 
been based on KRAS mutation status it is important to recognize that this pathway can be 
activated by multiple mechanisms. There are also potential clinical differences in the type of 
KRAS mutations, and it possible that additional mutations (e.g. Lkb1 mutations) or molecular 
events may influence the activity of MEK inhibitors. The similar activity of MEK inhibitors 
in KRAS mutant and wild-type NSCLC suggest KRAS mutation status alone is not the 
optimal predictive biomarker for further development of MEK inhibitors. The development 
of a predictive biomarker for MEK inhibitors will be critical to further development of this 
class of agents.
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MEK inhibitors have been investigated in NSCLC, predominantly in patients with KRAS 
mutant NSCLC
The type of KRAS mutations or other mutations may influence the activity of MEK 
inhibitors.
Mechanisms other than KRAS mutations may activated this the MAPK kinase pathway
MEK inhibitors in combination with chemotherapy have revealed the most promising 
activity.
KRAS mutation status alone does not appear to be a biomarker of MEK inhibitor efficacy
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The ERK1/2 MAPK signaling network includes a MAP3K including BRAF and RAF1 that 
are activated by RAS. Additional MAP3Ks can activate the MAPK signaling network 
including MAP3K8 (TPL2/COT) and MAP3K1 (MEKK1). MAP3Ks phosphorylate and 
activate MEK1/2 which phosphorylates and activates ERK1/2. ERK1/2 phosphorylate and 
regulate the activity of many different proteins controlling important cellular functions 
required for cell survival and proliferation. Dabrafenib and vemurafenib are inhibitors 
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targeting activated BRAF. Selumetinib and trametinib are allosteric inhibitors of MEK1/2. 
SCH771984 is an ERK1/2 inhibitor in early stage clinical trials.
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